Clinical Trials
48 trialsCyto-KIK
Columbia University
AtezoCab
University of Utah
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
SAMURAI
NRG Oncology
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
CaboPoint
Ipsen
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
SKIPPY 2
Leiden University Medical Center
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Dana-Farber Cancer Institute
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
CABRAMET
Centre Leon Berard
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ABATE
Hoosier Cancer Research Network
PemCab
University of Utah
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Fundacion Oncosur
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
CANTATA
Calithera Biosciences, Inc
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
SPARC
Duke University
Cabo-POLARIS
Centre Hospitalier Universitaire de Besancon
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
CabUC
Johannes Gutenberg University Mainz
BONSAI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
BREAKPOINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ARCADIA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
Asan Medical Center
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
Cabozantinib in Men With Castration-Resistant Prostate Cancer
University of Washington
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Cedars-Sinai Medical Center